Quality Systems – Page 52

Breakdown repair undocumented after equipment breakdown – calibration/PM evidence pack checklist

Undocumented Equipment Breakdown Repairs: A Comprehensive Investigation Approach Breakdowns of manufacturing equipment can lead to significant disruptions, especially when repairs are undocumented. Such situations may raise substantial concerns during audits…

Formulation robustness underestimated during transfer to manufacturing – data package improvements for filing

“`html Underestimating Formulation Robustness During the Manufacturing Transfer: A Comprehensive Investigation In the pharmaceutical industry, the seamless transition from formulation development to manufacturing is critical for maintaining product quality and…

Unplanned maintenance intervention after equipment breakdown – preventing repeat deviations via reliability strategy

Addressing Equipment Breakdowns: Investigating Unplanned Maintenance Interventions in Pharma Operations In pharmaceutical manufacturing, equipment breakdowns can lead to unplanned maintenance interventions, often triggering a cascade of quality issues, inefficiencies, and…

Excipient variability impact during transfer to manufacturing – downstream GMP risk and prevention

Understanding the Effects of Excipient Variability During the Manufacturing Transfer Process In the highly regulated pharmaceutical environment, the transfer of excipients from R&D to manufacturing can pose significant challenges that…

Calibration failure discovered during changeover maintenance – preventing repeat deviations via reliability strategy

Understanding Calibration Failures During Changeover Maintenance and Strategies for Prevention Calibration failures can occur during changeover maintenance and present significant challenges in pharmaceutical manufacturing. These incidents can lead to deviations,…

Design space poorly justified during comparability assessment – data package improvements for filing

Improving Data Package Justifications for Design Space During Comparability Assessments In the pharmaceutical industry, the integrity of data packages submitted for regulatory scrutiny can make or break the approval of…

Utilities excursion event after equipment breakdown – how to defend maintenance decisions to inspectors

Understanding Utilities Excursion Events After Equipment Breakdowns: A Structured Investigation Approach Utilities excursion events often present significant challenges in pharmaceutical operations, particularly following an equipment breakdown. These excursions can lead…

Post-approval change misclassified during post-approval maintenance – FDA/EMA expectations and how to respond

“`html Addressing Misclassification of Post-Approval Changes During Maintenance in Compliance with FDA and EMA Guidelines In the pharmaceutical manufacturing landscape, accurate classification and documentation of post-approval changes are paramount to…

Unplanned maintenance intervention during inspection walkthrough – how to defend maintenance decisions to inspectors

Understanding the Impacts of Unplanned Maintenance Interventions During Regulatory Inspections In the highly regulated pharmaceutical environment, effective maintenance and engineering practices are vital for maintaining compliance and ensuring product quality.…

CMC section queries unresolved during variation planning – how to avoid repeat deficiencies

Strategies for Addressing Unresolved CMC Section Queries in Variation Planning to Improve Regulatory Compliance In the highly regulated world of pharmaceutical manufacturing, unresolved queries related to Chemistry, Manufacturing, and Controls…

Recurring equipment stoppages during inspection walkthrough – root cause approach for recurring failures

Addressing Recurring Equipment Stoppages During Inspections: A Root Cause Analysis Approach Recurring equipment stoppages during inspection walkthroughs present significant hurdles in maintaining GMP compliance and operational efficiency. Such stoppages may…

Submission delayed due to data gaps during variation planning – FDA/EMA expectations and how to respond

Addressing Submission Delays Caused by Data Gaps in Variation Planning: An Investigation Approach In the pharmaceutical industry, a submission delay due to data gaps during variation planning can significantly impact…